#1Donal P. McLornan(Guy's and St Thomas' NHS Foundation Trust)H-Index: 25
#2Janet E. Pope(UWO: University of Western Ontario)H-Index: 81
Last. Claire N. Harrison(Guy's and St Thomas' NHS Foundation Trust)H-Index: 72
view all 0 authors...
Summary null An enhanced understanding of the importance of Janus kinase (JAK) and signal transducer and activator of transcription (STAT) signalling in multiple disease states has led to an increasing applicability of therapeutic intervention with JAK inhibitors. These agents have revolutionised treatments for a heterogeneous group of disorders, such as myeloproliferative neoplasms, rheumatoid arthritis, inflammatory bowel disease, and multiple immune-driven dermatological diseases, exemplifyin...
Last. Sung-Bae Kim(UOU: University of Ulsan)H-Index: 57
view all 0 authors...
Summary null null Background null First-line therapy for advanced oesophageal cancer is currently limited to fluoropyrimidine plus platinum-based chemotherapy. We aimed to evaluate the antitumour activity of pembrolizumab plus chemotherapy versus chemotherapy alone as first-line treatment in advanced oesophageal cancer and Siewert type 1 gastro-oesophageal junction cancer. null null null Methods null We did a randomised, placebo-controlled, double-blind, phase 3 study across 168 medical centres ...